# TKG Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/tkg-therapeutics

- Industry: Biotechnology
- Headquarters: Tokyo, Japan
- Website: www.tkg-na.com
- Total disclosed funding: $0.5M
- Latest round: Seed (Jan 31, 2024)
- Investors on record: 2

## About

Founded in 2022 and based in Tokyo, Japan, TKG Therapeutics, Inc. is a research and developer of cancer immunity drugs. As of 2024, the company is headed by its CEO Masaaki Matsui. In January 2024, the firm raised JPY 150 million in Seed funding from investors Real Tech Japan and MITSUBISHI GAS CHEMICAL COMPANY, INC.

The company offers nucleic acid-derived cancer medicine that will allow natural immunity to fight the disease. To create nucleic acid aggregates that target disease cells and are identified as foreign substances, the company pharmaceuticals employ miRNA, which is specifically overexpressed in cancer cells, as a biomarker. This triggers innate immunity and ultimately results in cancer cell death.

The company plans to use the January 2024 funding to develop its pharmaceutical formula, perform pre-clinical trials, and develop new machines for nucleic acid synthesis.

## Funding rounds

- Seed, Jan 31, 2024, $0.5M — UntroD Capital, MITSUBISHI GAS CHEMICAL COMPANY, INC.

## Investors

- UntroD Capital — Seed
- MITSUBISHI GAS CHEMICAL COMPANY, INC. — Seed